Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc at Stifel Healthcare Conference (Virtual) Transcript

Nov 15, 2021 / 08:20PM GMT
Release Date Price: €36.85 (+0.19%)
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thanks, everybody, for continuing to join on. It's my pleasure to be hosting a discussion with Barry Greene, CEO of Sage, who I and probably everyone listening have known for a long time since his Alnylam days. Barry, thanks again. Maybe you want to just do the sort of obligatory 3- to 4-minute kick off and give an update on zuranolone, SAGE-324, SAGE-718 and then we can get into more specifics.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Yes, absolutely, Paul. Thanks, and I'd like to thank Stifel for having us here today. As we set out in January and established the goals for this year, we have executed on the expand and accelerate strategy we set out. We've seen, as you know, positive readouts for zuranolone, SAGE-324 and SAGE-718. It's quite remarkable. And we've gotten clarity with the agency for our filing path along with filing path for zuranolone in the second half of 2022 with the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot